All Roll Calls
Yes: 298 • No: 80
OklahomaHB 3834Oklahoma 2026 Regular SessionHouse
Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act; terms; requirements for drug developers; contractual terms; intellectual property rights; reports; intellectual property account; effective date.
Sponsored By: Stan May (Republican)
Signed by Governor
Senate Committee
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Broader ibogaine access after approval
Contracts require a plan to make ibogaine treatment widely available in Oklahoma after FDA approval. The plan gives priority to Oklahoma residents and seeks insurance coverage. It must include ways to serve uninsured and low‑income people and train local providers.
Oklahoma backs ibogaine clinical trials
Beginning November 1, 2026, the State Department of Health can sign contracts to run multistate ibogaine trials, subject to available funds. Before a contract, developers must show an FDA path (trial design and Breakthrough Therapy plans), recruitment and aftercare steps, a multistate agreement, and sound finances. Contracts must require a dollar‑for‑dollar match and aim to use in‑state clinicians, sites, and participants. Developers must file quarterly electronic progress and spending reports on state and matching funds. The Department may adjust terms if the deal stays fair and gives the state equal value; eligible developers include public‑private, for‑profit, nonprofit, or public‑benefit groups with an ibogaine deal with at least one other state.
State gets share of ibogaine IP
The state claims a proportional share of patents, data, and other intellectual property created by the trials. Developers must pay the state's share during funding and commercialization. The money goes into a new Ibogaine Development Revolving Fund. The Department uses the fund for research or programs that help at‑risk people with conditions treatable by ibogaine. The fund can also receive gifts, grants, and appropriations and keeps money across years.
Doctors protected for recommending trials
Oklahoma‑licensed medical professionals are not disciplined solely for recommending that patients join ibogaine clinical trials. This protection applies only when the recommendation is the only reason for discipline.
Sponsors & Cosponsors
Sponsor
Stan May
Republican • House
Cosponsors
Avery Frix
Republican • Senate
Daniel Pae
Republican • House
Roll Call Votes
House vote • 5/6/2026
FOURTH READING
Yes: 69 • No: 21
Senate vote • 4/29/2026
THIRD READING
Yes: 33 • No: 9
Senate vote • 4/22/2026
Top_of_Page
Yes: 0 • No: 0
Senate vote • 4/22/2026
Committee vote: Appropriations
Yes: 20 • No: 0
Senate vote • 4/13/2026
Committee vote: Health & Human Services
Yes: 10 • No: 2
Senate vote • 4/13/2026
Top_of_Page
Yes: 0 • No: 2
House vote • 3/11/2026
THIRD READING
Yes: 68 • No: 23
House vote • 3/11/2026
Top_of_Page
Yes: 68 • No: 23
House vote • 2/19/2026
DO PASS
Yes: 10 • No: 0
House vote • 2/19/2026
DO PASS
Yes: 10 • No: 0
House vote • 2/11/2026
DO PASS
Yes: 5 • No: 0
House vote • 2/11/2026
DO PASS
Yes: 5 • No: 0
Actions Timeline
Approved by Governor 05/12/2026
5/12/2026HouseSent to Governor
5/6/2026HouseEnrolled measure signed, returned to House
5/6/2026SenateEnrolled, signed, to Senate
5/6/2026HouseReferred for enrollment
5/6/2026HouseFourth Reading, Measure passed: Ayes: 69 Nays: 21
5/6/2026HouseSA's read, adopted
5/6/2026HouseSA's received
4/30/2026HouseEngrossed to House
4/30/2026SenateReferred for engrossment
4/29/2026SenateMeasure passed: Ayes: 33 Nays: 9
4/29/2026SenateGeneral Order, Considered
4/29/2026SenatePlaced on General Order
4/27/2026SenateReported Do Pass, amended by committee substitute Appropriations committee; CR filed
4/22/2026SenateReferred to Appropriations
4/13/2026SenateReported Do Pass Health and Human Services committee; CR filed
4/13/2026SenateSecond Reading referred to Health and Human Services Committee then to Appropriations Committee
4/1/2026SenateFirst Reading
3/12/2026SenateEngrossed, signed, to Senate
3/12/2026HouseReferred for engrossment
3/11/2026HouseThird Reading, Measure passed: Ayes: 68 Nays: 23
3/11/2026HouseAmended
3/11/2026HouseGeneral Order
3/11/2026HouseCR; Do Pass Health and Human Services Oversight Committee
2/19/2026HouseAuthored by Senator Frix (principal Senate author)
2/11/2026House
Bill Text
Enrolled (final version)
5/6/2026
Amended And Engrossed
4/30/2026
Floor (Senate)
4/23/2026
Senate Committee Report 2
4/22/2026
Senate Committee Substitute for House Bill
4/22/2026
Senate Committee Report 1
4/13/2026
Engrossed
3/12/2026
Floor (House)
2/20/2026
House Committee Report
2/19/2026
House Policy Committee Report
2/11/2026
Introduced
1/15/2026
Related Bills
SB 423, Medical records; access; eliminating certain health care provider duties; authorizing certain fees. Effective date.
SB 633, Children; Children's Code; enacting Leo's Law; fentanyl testing; child endangerment; appropriating funds. Effective date.
SB 1618, Criminal procedure; creating the Public Protection Act; conditions of release; public safety reports. Effective date.
SB 1543, Driving under the influence; authorizing aggregation of certain offenses; creating felony offense. Effective date.
SB 1687, Driver licenses; adding certain age requirement to qualification for certain license; permitting certain persons to proctor certain examination. Effective date.
SB 1264, Crimes and punishment; Class A3 and B3 offenses; assault and battery; modifying certain definition; repealers. Effective date.